Adding Rituxan Boosts Outcomes in HIV-Associated NHLs
According to findings to be reported at the annual meeting of the American Society of Clinical Oncology, outcomes are improved when rituximab is added to standard chemotherapy in patients who are HIV positive and have developed non-Hodgkin's lymphoma.
Researchers from Albert Einstein College of Medicine in New York evaluated 16 clinical trials from the last decade going back to 2000 and involving over 1,100 patients. They sought to determine if there might be some clues to the most effective treatment for NHL patients with HIV, because currently there is no consensus.
Using overall survival, progression-free survival and complete response as primary endpoints, they found that the addition of the monoclonal antibody rituximab could be associated with several factors, notably better rates in:
-- Complete response
-- Progression-free survival
-- Overall survival
Each of the three endpoints. Additionally, the combination chemotherapy regimen EPOCH out-performed CHOP in all three endpoints.
Source: Medpage Today
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
